Publications by authors named "Kelechi Lauretta Adejumo"
Background: As the frequency of nonalcoholic fatty liver disease (NAFLD) continues to rise in the United States (US) community, more patients are hospitalized with NAFLD. However, data on the prevalence and outcomes of hospitalizations with NAFLD are lacking. We investigated the prevalence, trends and outcomes of NAFLD hospitalizations in the US.
View Article and Find Full Text PDFObjectives: Chronic pancreatitis (CP) is associated with high rates of recurrent hospitalizations, which predisposes to Clostridium difficile infection (CDI). We investigate the burden of CDI in CP.
Methods: We identified records of patients with CP from the Nationwide Inpatient Sample (NIS) 2012-2014 and estimated the impact of CDI on their outcomes.
Background: Cirrhotic cardiomyopathy, hyperammonemia, and hepatorenal syndrome predispose to cardiac arrhythmias in End-stage liver disease (ESLD).
Objectives: Among ESLD hospitalizations, we evaluate the distribution and predictors of arrhythmias and their impact on hospitalization outcomes.
Methods: We selected ESLD records from the Nationwide Inpatient Sample (2007-2014), identified concomitant arrhythmias (tachyarrhythmias and bradyarrhythmias), and their demographic and comorbid characteristics, and estimated the effect of arrhythmia on outcomes (SAS 9.
Background: Protein-energy malnutrition (PEM) diminishes amino acid and energy availability, impairing the body's healing capability after injury, such as in myocardial damage following acute myocardial infarction (AMI).
Aims: We sought to investigate the influence of PEM on clinical outcomes of AMI.
Methods: We identified records with a primary discharge diagnosis of AMI from the Nationwide Inpatient Sample (2012-2014), stratified by concomitant PEM.
Chronically elevated cytokines from un-abating low-grade inflammation in heart failure (HF) results in Protein-Energy Malnutrition (PEM). However, the impact of PEM on clinical outcomes of admissions for HF exacerbations has not been evaluated in a national data. From the 2012 to 2014 Nationwide Inpatient Sample (NIS) patient's discharge records for primary HF admissions, we identified patients with concomitant PEM, and their demographic and comorbid factors.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated the effects of cannabis use on pancreatitis by analyzing data from over 15 million inpatient records between 2012 and 2014, focusing on three groups: gallstone patients, alcohol abusers, and those without these conditions.
- - Results showed that cannabis use alongside alcohol reduced the incidence of acute and chronic pancreatitis, while it had no effect on gallstone-related pancreatitis and increased chronic pancreatitis risk in non-alcohol, non-gallstone users.
- - The conclusion indicates a potential protective effect of cannabis against alcohol-related pancreatitis but suggests it may increase chronic pancreatitis risk in certain populations.
Article Synopsis
- The study investigates the relationship between cannabis use and alcoholic gastritis among adults with risky alcohol consumption, analyzing data from over 316,000 hospital discharge records from 2014.
- Results show that cannabis users had a significantly lower prevalence of alcoholic gastritis compared to non-cannabis users, indicating a 25% decrease in the probability of developing this condition.
- The findings suggest that cannabis may counteract some harmful effects of alcohol on the stomach, highlighting the need for further research into potential treatments for alcoholic gastritis using cannabis extracts as laws around cannabis use become more permissive.
Background And Aim: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals.
Methods: We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis.
Cannabis use is associated with reduced prevalence of obesity and diabetes mellitus (DM) in humans and mouse disease models. Obesity and DM are a well-established independent risk factor for non-alcoholic fatty liver disease (NAFLD), the most prevalent liver disease globally. The effects of cannabis use on NAFLD prevalence in humans remains ill-defined.
View Article and Find Full Text PDF